36 items found in 5 pages
TINs Webinar: Nanoparticle formulations for therapeutic nucleic acid delivery
The development of mRNA based vaccines delivered in lipid nanoparticles (LNPs) has led to a surge of interest in the possible use of LNP mRNA formulation as a treatment for a range of other diseases. During this webinar, Prof. Steve Hart from the Department of Genetics & Genomic Medicine, will introduce nanoparticle technologies and the design and production of mRNA for their use in the development of therapeutics. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
13
8/2/2024
TINs Webinar: Bioprinting for preclinical research and beyond
Preclinical research struggles with limitations that hinder progress. In this webinar, Professor Kalaskar, from the Department of Ortho and MSK Science, will explain how bioprinting technology could address these challenges and offer a game-changing solution. He will present how bioprinting can revolutionise the field by showcasing specific innovations developed by his team. The seminar will conclude with insights on the evolving regulatory landscape, including a discussion on the FDA Modernization Act 2 and its potential impact on future pre-clinical and clinical research.
20
7/17/2024
TINs Webinar: Phage display technology for the identification of peptides and glycopeptide ligands
Phage display is a recombinant screening technology that involves the construction of bacteriophage libraries that express large numbers (1*10^11) of peptides or proteins as fusions to the major or minor coat proteins of bacteriophage species such as M13. Phage display is routinely used in the pharmaceutical industry to develop fully human antibodies against a range of different diseases targets, including cancer and inflammatory diseases. Dr Chris Morris, from the School of Pharmacy, presented examples of how phage display can be applied to the identification of peptide-based motifs for targeting biological structures at three different length scales – whole cells in melanoma skin cancer, individual glycan-binding proteins in human lung infections and subcellular, non-canonical DNA structures.
11
6/6/2024
TINs Webinar: Formulations of RNAs and antibodies for pulmonary delivery
This session will unravel the complexities of developing inhaled formulations of biologics for the treatment of respiratory diseases such as severe asthma, viral infections, and cystic fibrosis. In her presentation, Dr Jenny Lam from the School of Pharmacy will give an overview of the use of particle engineering techniques and formulation strategies to overcome the delivery barriers. She will also introduce the spray drying technology, a versatile and scalable particle engineering technique that has been investigated for producing dry powder formulation of biologics with good stability (avoid cold-chain logistics) and aerosolisation properties for inhalation. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments.
22
5/23/2024
TINs Webinar: Overview of UCL Mass Spectrometry Science Technology Platform
In this presentation, Prof. Thalassinos from the Institute of Structural and Molecular Biology explored the functionalities of the UCL Mass Spectrometry Science Technology Platform, focusing on its mass spectrometry capabilities. He will also highlight several recent research projects that have been made possible due to this remarkable technology. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
8
5/23/2024
UCL TINs Industry Club - Discovery Webinar
UCL is launching a major new initiative called TINs Industry Club, an opportunity for industry partners to engage the UCL Therapeutic Innovation Networks (TINs) to identify & address company R&D challenges, and to hear the latest UCL research for potential co-development. In this webinar, we showcased six areas of strength for the therapeutic modality Small Molecules that we think are ripe for collaboration.
8
5/23/2024
TINs Webinar: LMCB electron microscopy imaging facilities
Electron microscopy (EM) provides ultrastructural information at nanometre resolution which, when combined with a wide variety of sample preparation techniques and multimodal approaches, can be an exceptionally powerful research tool. With continual advances being made, and for example volume EM being named by Nature as “One of the seven technologies to watch in 2023”, Jemima Burden, Head of Electron Microscopy at the Laboratory for Molecular Cell Biology, will share some of the approaches available to address research questions related to basic cell and developmental biology, through to virology, immunology, neurodegenerative diseases, regeneration, cancer biology and drug and therapeutic development. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit.
10
4/15/2024
TINs Webinar: Antisense oligonucleotides as potential treatments for inherited retinal dystrophies
Antisense oligonucleotides (AONs) can be used to alter many aspects of gene expression, from splice isoform switching to reducing, or increasing, gene expression. The retina is an accessible part of the nervous system and is an ideal paradigm to study how AONs can be used to combat neurodegeneration. During this webinar, Prof. Mike Cheetham from the Institute of Ophthalmology will give an overview of AON design and show how they can be used as therapies for inherited retinal dystrophies (IRDs), from stem cell derived models of disease, to in vivo and clinical trials. This will exemplify the potential of AONs to treat genetic disease, and IRDs in particular. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biome
22
3/27/2024
12345 >